Gloria Huang, MD, FACOG

• Abdelrahman AlAshqar
• Abhijit Patel
• Alessandro Santin
• Amy Stiegler
• Blair Colette McNamara
• Gary Altwerger
• Henry S. Park
• Herbert Yu
• Jun Deng
• Levent Mutlu
• Masoud Azodi
• Melissa Rasar Young
• Mitchell Clark
• Natalia Buza
• Nupur Nagarkatti
• Pei Hui
• Peter Schwartz
• Shari Damast
• Stefania Bellone
• Vaagn Andikyan
• Yang Yang
• Zhigui Li

Genital Neoplasms, Female; Neoplasm Metastasis; Neoplasms, Hormone-Dependent; Ovarian Neoplasms; Pelvic Neoplasms; Uterine Neoplasms; Endometrial Neoplasms; Genomics

• ICG Fluorescence Technique for Detection of Sentinel Lymph Nodes in Laparoscopic Endometrial Cancer StagingAlAshqar A, Mutlu L, McNamara B, Harold J, Clark M, Huang G, Azodi M, Schwartz P, Santin A, Ratner E, Altwerger G, Andikyan V. ICG Fluorescence Technique for Detection of Sentinel Lymph Nodes in Laparoscopic Endometrial Cancer Staging. Journal Of Minimally Invasive Gynecology 2023, 30: s36. DOI: 10.1016/j.jmig.2023.08.110.
• In vivo and in vitro efficacy of trastuzumab deruxtecan in uterine serous carcinoma.Mutlu L, Manavella D, Bellone S, McNamara B, Harold J, Mauricio D, Siegel E, Buza N, Hui P, Hartwich T, Yang-Hartwich Y, Demirkiran C, Verzosa M, Altwerger G, Ratner E, Huang G, Clark M, Andikyan V, Azodi M, Dottino P, Schwartz P, Santin A. In vivo and in vitro efficacy of trastuzumab deruxtecan in uterine serous carcinoma. Molecular Cancer Therapeutics 2023 PMID: 37676984, DOI: 10.1158/1535-7163.mct-23-0126.
• Uterine Leiomyosarcomas harboring MAP2K4 gene amplification are markedly sensitive in vivo to PLX8725, a Novel MAP2K4 Inhibitor (1315)McNamara B, Harold J, Manavella D, Bellone S, Mutlu L, Hartwich T, Zipponi M, Yang-Hartwich Y, Demirkiran C, Verzosa M, Choi J, Dong W, Buza N, Hui P, Altwerger G, Huang G, Andikyan V, Clark M, Ratner E, Azodi M, Schwartz P, Schlessinger J, Santin A. Uterine Leiomyosarcomas harboring MAP2K4 gene amplification are markedly sensitive in vivo to PLX8725, a Novel MAP2K4 Inhibitor (1315). Gynecologic Oncology 2023, 176: s193. DOI: 10.1016/j.ygyno.2023.06.218.
• Hyperthermic Intraperitoneal Chemotherapy in Ovarian CancerGelissen J, Adjei N, McNamara B, Mutlu L, Harold J, Clark M, Altwerger G, Dottino P, Huang G, Santin A, Azodi M, Ratner E, Schwartz P, Andikyan V. Hyperthermic Intraperitoneal Chemotherapy in Ovarian Cancer. Annals Of Surgical Oncology 2023, 30: 5597-5609. PMID: 37358686, DOI: 10.1245/s10434-023-13757-0.
• Preliminary results of a phase II trial with sacituzumab govitecan-hziy in patients with recurrent endometrial carcinoma overexpressing Trop-2.Santin A, McNamara B, Siegel E, Harold J, Mutlu L, Altwerger G, Huang G, Andikyan V, Clark M, Ratner E, Azodi M, Dottino P, Schwartz P, Bellone S. Preliminary results of a phase II trial with sacituzumab govitecan-hziy in patients with recurrent endometrial carcinoma overexpressing Trop-2. Journal Of Clinical Oncology 2023, 41: 5599-5599. DOI: 10.1200/jco.2023.41.16_suppl.5599.
• Abstract 3402: In vivo efficacy of RAF/MEK clamp avutometinib (VS-6766) in combination with FAK inhibition in low grade serous ovarian cancerMcNamara B, Demirkiran C, Bellone S, Mutlu L, Zipponi M, Verzosa M, Harold J, Hartwich T, Altwerger G, Ratner E, Huang G, Clark M, Andikyan V, Azodi M, Schwartz P, Dottino P, Santin A. Abstract 3402: In vivo efficacy of RAF/MEK clamp avutometinib (VS-6766) in combination with FAK inhibition in low grade serous ovarian cancer. Cancer Research 2023, 83: 3402-3402. DOI: 10.1158/1538-7445.am2023-3402.
• Uterine leiomyosarcomas harboring MAP2K4 gene amplification are sensitive in vivo to PLX8725, a novel MAP2K4 inhibitorMcNamara B, Harold J, Manavella D, Bellone S, Mutlu L, Hartwich T, Zipponi M, Yang-Hartwich Y, Demirkiran C, Verzosa M, Yang K, Choi J, Dong W, Buza N, Hui P, Altwerger G, Huang G, Andikyan V, Clark M, Ratner E, Azodi M, Schwartz P, Burton E, Inagaki H, Albers A, Zhang C, Bollag G, Schlessinger J, Santin A. Uterine leiomyosarcomas harboring MAP2K4 gene amplification are sensitive in vivo to PLX8725, a novel MAP2K4 inhibitor. Gynecologic Oncology 2023, 172: 65-71. PMID: 36958197, PMCID: PMC10192120, DOI: 10.1016/j.ygyno.2023.03.009.
• The Poly (ADP-ribose) polymerase inhibitor olaparib and pan-ErbB inhibitor neratinib are highly synergistic in HER2 overexpressing epithelial ovarian carcinoma in vitro and in vivoHan C, McNamara B, Bellone S, Harold J, Manara P, Hartwich T, Mutlu L, Yang-Hartwich Y, Zipponi M, Demirkiran C, Verzosa M, Altwerger G, Ratner E, Huang G, Clark M, Andikyan V, Azodi M, Dottino P, Schwartz P, Santin A. The Poly (ADP-ribose) polymerase inhibitor olaparib and pan-ErbB inhibitor neratinib are highly synergistic in HER2 overexpressing epithelial ovarian carcinoma in vitro and in vivo. Gynecologic Oncology 2023, 170: 172-178. PMID: 36706643, PMCID: PMC10023457, DOI: 10.1016/j.ygyno.2023.01.015.
• Trastuzumab deruxtecan (DS-8201a), a HER2-targeting antibody–drug conjugate with topoisomerase I inhibitor payload, shows antitumor activity in uterine and ovarian carcinosarcoma with HER2/neu expressionMauricio D, Bellone S, Mutlu L, McNamara B, Manavella D, Demirkiran C, Verzosa M, Buza N, Hui P, Hartwich T, Harold J, Yang-Hartwich Y, Zipponi M, Altwerger G, Ratner E, Huang G, Clark M, Andikyan V, Azodi M, Schwartz P, Santin A. Trastuzumab deruxtecan (DS-8201a), a HER2-targeting antibody–drug conjugate with topoisomerase I inhibitor payload, shows antitumor activity in uterine and ovarian carcinosarcoma with HER2/neu expression. Gynecologic Oncology 2023, 170: 38-45. PMID: 36610380, PMCID: PMC10445234, DOI: 10.1016/j.ygyno.2022.12.018.
• What role does adjuvant therapy play in the management of endometrial cancer?Huang G, Tymon-Rosario J, Santin A. What role does adjuvant therapy play in the management of endometrial cancer? Expert Opinion On Pharmacotherapy 2023, 24: 7-10. PMID: 36594708, DOI: 10.1080/14656566.2022.2157207.
• Ovarian and uterine carcinosarcomas are sensitive in vitro and in vivo to elimusertib, a novel ataxia-telangiectasia and Rad3-related (ATR) kinase inhibitorManavella D, McNamara B, Harold J, Bellone S, Hartwich T, Yang-Hartwich Y, Mutlu L, Zipponi M, Demirkiran C, Verzosa M, Altwerger G, Ratner E, Huang G, Clark M, Andikyan V, Azodi M, Schwartz P, Dottino P, Choi J, Alexandrov L, Buza N, Hui P, Santin A. Ovarian and uterine carcinosarcomas are sensitive in vitro and in vivo to elimusertib, a novel ataxia-telangiectasia and Rad3-related (ATR) kinase inhibitor. Gynecologic Oncology 2022, 169: 98-105. PMID: 36525930, PMCID: PMC9925406, DOI: 10.1016/j.ygyno.2022.12.003.
• EP007/#994 Bay 1895344, a novel ATR inhibitor, demonstrates in vivo activity against ATRX altered uterine leiomyosarcomaHarold J, Manavella D, Bellone S, Siegel E, Hartwich T, Zammataro L, Mutlu L, Altwerger G, Menderes G, Ratner E, Huang G, Clark M, Andikyan V, Azodi M, Schwartz P, Alexandrov L, Santin A. EP007/#994 Bay 1895344, a novel ATR inhibitor, demonstrates in vivo activity against ATRX altered uterine leiomyosarcoma. 2022, a51.1-a51. DOI: 10.1136/ijgc-2022-igcs.98.
• Elimusertib (BAY1895344), a novel ATR inhibitor, demonstrates in vivo activity in ATRX mutated models of uterine leiomyosarcomaHarold J, Bellone S, Manavella D, Mutlu L, McNamara B, Hartwich T, Zipponi M, Yang-Hartwich Y, Demirkiran C, Verzosa M, Choi J, Dong W, Buza N, Hui P, Altwerger G, Huang G, Andikyan V, Clark M, Ratner E, Azodi M, Schwartz P, Santin A. Elimusertib (BAY1895344), a novel ATR inhibitor, demonstrates in vivo activity in ATRX mutated models of uterine leiomyosarcoma. Gynecologic Oncology 2022, 168: 157-165. PMID: 36442427, PMCID: PMC9797429, DOI: 10.1016/j.ygyno.2022.11.014.
• Intersections of endocrine pathways and the epithelial mesenchymal transition in endometrial cancerGelissen JH, Huang GS. Intersections of endocrine pathways and the epithelial mesenchymal transition in endometrial cancer. Frontiers In Oncology 2022, 12: 914405. PMID: 36052252, PMCID: PMC9424890, DOI: 10.3389/fonc.2022.914405.
• BAY1895344, a novel ataxia telangiectasia and RAD3-related (ATR) inhibitor, is active in vivo against ATRX mutated uterine leiomyosarcoma (212)Harold J, Manavella D, Bellone S, Siegel E, Mauricio D, Hartwich T, Zammataro L, Mutlu L, AlAshqar A, Altwerger G, Menderes G, Ratner E, Huang G, Clark M, Andikyan V, Azodi M, Schwartz P, Alexandrov L, Santin A. BAY1895344, a novel ataxia telangiectasia and RAD3-related (ATR) inhibitor, is active in vivo against ATRX mutated uterine leiomyosarcoma (212). Gynecologic Oncology 2022, 166: s118. DOI: 10.1016/s0090-8258(22)01437-8.
• Trastuzumab deruxtecan (DS-8201a), a HER2-Targeting Antibody-Drug Conjugate with Topoisomerase I Inhibitor Payload, Shows Antitumor Activity in Uterine and Ovarian Carcinosarcoma with HER2/neu Expression (046)Mauricio D, Bellone S, Manavella D, Harold J, Buza N, Altwerger G, Menderes G, Ratner E, Huang G, Clark M, Andikyan V, Azodi M, Schwartz P, Santin A. Trastuzumab deruxtecan (DS-8201a), a HER2-Targeting Antibody-Drug Conjugate with Topoisomerase I Inhibitor Payload, Shows Antitumor Activity in Uterine and Ovarian Carcinosarcoma with HER2/neu Expression (046). Gynecologic Oncology 2022, 166: s31-s32. DOI: 10.1016/s0090-8258(22)01265-3.
• Ovarian and uterine carcinosarcoma cell lines show preclinical sensitivity to BAY 1895344, a novel ataxia-telangiectasia and Rad3-related (ATR) kinase inhibitor (011)Manavella D, Harold J, Bellone S, Hartwich T, Mutlu L, Tymon-Rosario J, Siegel E, Altwerger G, Menderes G, Ratner E, Huang G, Clark M, Andikyan V, Azodi M, Schwartz P, Alexandrov L, Santin A. Ovarian and uterine carcinosarcoma cell lines show preclinical sensitivity to BAY 1895344, a novel ataxia-telangiectasia and Rad3-related (ATR) kinase inhibitor (011). Gynecologic Oncology 2022, 166: s9. DOI: 10.1016/s0090-8258(22)01229-x.
• Homologous recombination deficiency (HRD) signature-3 in ovarian and uterine carcinosarcomas correlates with preclinical sensitivity to Olaparib, a Poly (adenosine diphosphate [ADP]-ribose) polymerase (PARP) inhibitor (043)Tymon-Rosario J, Manara P, Manavella D, Bellone S, Siegel E, Hartwich T, Harold J, Zammataro L, Yang-Hartwich Y, Mutlu L, Altwerger G, Menderes G, Ratner E, Huang G, Clark M, Andikyan V, Azodi M, Schwartz P, Alexandrov L, Santin A. Homologous recombination deficiency (HRD) signature-3 in ovarian and uterine carcinosarcomas correlates with preclinical sensitivity to Olaparib, a Poly (adenosine diphosphate [ADP]-ribose) polymerase (PARP) inhibitor (043). Gynecologic Oncology 2022, 166: s30. DOI: 10.1016/s0090-8258(22)01262-8.
• In Vivo and In Vitro Efficacy of Enhertu in Uterine Serous Carcinoma (047)Mutlu L, Manavella D, Bellone S, Harold J, Mauricio D, Tymon-Rosario J, Siegel E, Hartwich T, Altwerger G, Menderes G, Ratner E, Huang G, Clark M, Andikyan V, Azodi M, Schwartz P, Santin A. In Vivo and In Vitro Efficacy of Enhertu in Uterine Serous Carcinoma (047). Gynecologic Oncology 2022, 166: s32-s33. DOI: 10.1016/s0090-8258(22)01266-5.
• ARID1A deficiency as a biomarker for sensitivity to radiation and ATR inhibition (232)Li J, Li Z, Soble W, Baro M, Lee H, Damast S, Contessa J, Huang G. ARID1A deficiency as a biomarker for sensitivity to radiation and ATR inhibition (232). Gynecologic Oncology 2022, 166: s128. DOI: 10.1016/s0090-8258(22)01456-1.
• Synergistic activity of neratinib in combination with olaparib in uterine serous carcinoma overexpressing HER2/neuYadav G, Roque DM, Bellone S, Manavella DD, Hartwich TMP, Zipponi M, Harold J, Tymon-Rosario J, Mutlu L, Altwerger G, Menderes G, Ratner E, Buza N, Hui P, Huang GS, Andikyan V, Clark M, Azodi M, Schwartz PE, Alexandrov LB, Santin AD. Synergistic activity of neratinib in combination with olaparib in uterine serous carcinoma overexpressing HER2/neu. Gynecologic Oncology 2022, 166: 351-357. PMID: 35641325, DOI: 10.1016/j.ygyno.2022.05.021.
• Homologous recombination deficiency (HRD) signature-3 in ovarian and uterine carcinosarcomas correlates with preclinical sensitivity to Olaparib, a poly (adenosine diphosphate [ADP]- ribose) polymerase (PARP) inhibitorTymon-Rosario JR, Manara P, Manavella DD, Bellone S, Hartwich TMP, Harold J, Yang-Hartwich Y, Zipponi M, Choi J, Jeong K, Mutlu L, Yang K, Altwerger G, Menderes G, Ratner E, Huang GS, Clark M, Andikyan V, Azodi M, Schwartz PE, Alexandrov LB, Santin AD. Homologous recombination deficiency (HRD) signature-3 in ovarian and uterine carcinosarcomas correlates with preclinical sensitivity to Olaparib, a poly (adenosine diphosphate [ADP]- ribose) polymerase (PARP) inhibitor. Gynecologic Oncology 2022, 166: 117-125. PMID: 35599167, DOI: 10.1016/j.ygyno.2022.05.005.
• Randomised phase II trial of weekly ixabepilone ± biweekly bevacizumab for platinum-resistant or refractory ovarian/fallopian tube/primary peritoneal cancerRoque DM, Siegel ER, Buza N, Bellone S, Silasi DA, Huang GS, Andikyan V, Clark M, Azodi M, Schwartz PE, Rao GG, Reader JC, Hui P, Tymon-Rosario JR, Harold J, Mauricio D, Zeybek B, Menderes G, Altwerger G, Ratner E, Santin AD. Randomised phase II trial of weekly ixabepilone ± biweekly bevacizumab for platinum-resistant or refractory ovarian/fallopian tube/primary peritoneal cancer. British Journal Of Cancer 2022, 126: 1695-1703. PMID: 35149854, PMCID: PMC8853032, DOI: 10.1038/s41416-022-01717-6.
• A phase 2 evaluation of pembrolizumab for recurrent Lynch‐like versus sporadic endometrial cancers with microsatellite instabilityBellone S, Roque DM, Siegel ER, Buza N, Hui P, Bonazzoli E, Guglielmi A, Zammataro L, Nagarkatti N, Zaidi S, Lee J, Silasi D, Huang GS, Andikyan V, Damast S, Clark M, Azodi M, Schwartz PE, Tymon‐Rosario J, Harold JA, Mauricio D, Zeybek B, Menderes G, Altwerger G, Ratner E, Alexandrov LB, Iwasaki A, Kong Y, Song E, Dong W, Elvin JA, Choi J, Santin AD. A phase 2 evaluation of pembrolizumab for recurrent Lynch‐like versus sporadic endometrial cancers with microsatellite instability. Cancer 2021, 128: 1206-1218. PMID: 34875107, PMCID: PMC9465822, DOI: 10.1002/cncr.34025.
• Financial toxicity in patients with gynecologic malignancies: a cross sectional studyZeybek B, Webster E, Pogosian N, Tymon-Rosario J, Balch A, Altwerger G, Clark M, Menderes G, Huang G, Azodi M, Ratner ES, Schwartz PE, Santin AD, Andikyan V. Financial toxicity in patients with gynecologic malignancies: a cross sectional study. Journal Of Gynecologic Oncology 2021, 32: e87. PMID: 34431257, PMCID: PMC8550931, DOI: 10.3802/jgo.2021.32.e87.
• Two-Port Robotic Laparoscopic HysterectomyMauricio D, Webster E, Harold J, Altwerger G, Azodi M, Clark M, Huang G, Menderes G, Ratner E, Santin A, Schwartz P, Andikyan V. Two-Port Robotic Laparoscopic Hysterectomy. Journal Of Minimally Invasive Gynecology 2021, 28: s155. DOI: 10.1016/j.jmig.2021.09.315.
• Prognostic Impact of Mismatch Repair Deficiency in High- and Low-Intermediate Risk, Early-Stage Endometrial Cancer Following Vaginal BrachytherapyLi J, Park H, Huang G, Young M, Ratner E, Santin A, Damast S. Prognostic Impact of Mismatch Repair Deficiency in High- and Low-Intermediate Risk, Early-Stage Endometrial Cancer Following Vaginal Brachytherapy. International Journal Of Radiation Oncology • Biology • Physics 2021, 111: s138. DOI: 10.1016/j.ijrobp.2021.07.311.
• Prognostic impact of mismatch repair deficiency in high- and low-intermediate-risk, early-stage endometrial cancer following vaginal brachytherapyLi JY, Park HS, Huang GS, Young MR, Ratner E, Santin A, Damast S. Prognostic impact of mismatch repair deficiency in high- and low-intermediate-risk, early-stage endometrial cancer following vaginal brachytherapy. Gynecologic Oncology 2021, 163: 557-562. PMID: 34602287, DOI: 10.1016/j.ygyno.2021.09.018.
• DHES0815A, a novel antibody-drug conjugate targeting HER2/neu, is highly active against uterine serous carcinomas in vitro and in vivoTymon-Rosario J, Bonazzoli E, Bellone S, Manzano A, Pelligra S, Guglielmi A, Gnutti B, Nagarkatti N, Zeybek B, Manara P, Zammataro L, Harold J, Mauricio D, Buza N, Hui P, Altwerger G, Menderes G, Ratner E, Clark M, Andikyan V, Huang GS, Silasi DA, Azodi M, Schwartz PE, Santin AD. DHES0815A, a novel antibody-drug conjugate targeting HER2/neu, is highly active against uterine serous carcinomas in vitro and in vivo. Gynecologic Oncology 2021, 163: 334-341. PMID: 34452746, PMCID: PMC8722447, DOI: 10.1016/j.ygyno.2021.08.014.
• Trastuzumab tolerability in the treatment of advanced (stage III-IV) or recurrent uterine serous carcinomas that overexpress HER2/neuTymon-Rosario J, Siegel ER, Bellone S, Harold J, Adjei N, Zeybek B, Mauricio D, Altwerger G, Menderes G, Ratner E, Clark M, Andikyan V, Huang GS, Azodi M, Schwartz PE, Fader AN, Santin AD. Trastuzumab tolerability in the treatment of advanced (stage III-IV) or recurrent uterine serous carcinomas that overexpress HER2/neu. Gynecologic Oncology 2021, 163: 93-99. PMID: 34372971, PMCID: PMC8721852, DOI: 10.1016/j.ygyno.2021.07.033.
• Randomized phase II trial of weekly ixabepilone with or without biweekly bevacizumab for platinum-resistant or refractory ovarian/fallopian tube/primary peritoneal cancerRoque D, Siegel E, Buza N, Bellone S, Silasi D, Huang G, Andikyan V, Clark M, Azodi M, Schwartz P, Rao G, Reader J, Hui P, Tymon-Rosario J, Harold J, Mauricio D, Zeybek B, Menderes G, Altwerger G, Ratner E, Santin A. Randomized phase II trial of weekly ixabepilone with or without biweekly bevacizumab for platinum-resistant or refractory ovarian/fallopian tube/primary peritoneal cancer. Gynecologic Oncology 2021, 162: s58. DOI: 10.1016/s0090-8258(21)00753-8.
• Charlson Comorbidity Index as a predictor of postoperative complication in octogenarians and nonagenarians with stage I endometrioid endometrial cancer: a single-institution retrospective reviewWebster E, Arkfeld C, Chang Y, Yadav G, Zeybek B, Tymon-Rosario J, Harold J, Clark M, Andikyan V, Huang G, Menderes G, Azodi M, Santin A, Schwartz P, Ratner E, Altwerger G. Charlson Comorbidity Index as a predictor of postoperative complication in octogenarians and nonagenarians with stage I endometrioid endometrial cancer: a single-institution retrospective review. Gynecologic Oncology 2021, 162: s108. DOI: 10.1016/s0090-8258(21)00848-9.
• Financial toxicity in patients with gynecologic malignanciesZeybek B, Webster E, Pogosian N, Tymon-Rosario J, Mauricio D, Harold J, Menderes G, Altwerger G, Malette J, Luther M, Baker L, Balch A, Clark M, Huang G, Azodi M, Ratner E, Schwartz P, Santin A, Andikyan V. Financial toxicity in patients with gynecologic malignancies. Gynecologic Oncology 2021, 162: s162. DOI: 10.1016/s0090-8258(21)00950-1.
• In vitro and in vivo activity of DHES0815A, an antibody-drug conjugate targeting HER2/neu in uterine serous carcinomaTymon-Rosario J, Bonazzoli E, Guglielmi A, Bellone S, Nagarkatti N, Zammataro L, Zeybek B, Harold J, Mauricio D, Clark M, Andikyan V, Huang G, Altwerger G, Menderes G, Azodi M, Ratner E, Schwartz P, Santin A. In vitro and in vivo activity of DHES0815A, an antibody-drug conjugate targeting HER2/neu in uterine serous carcinoma. Gynecologic Oncology 2021, 162: s186-s187. DOI: 10.1016/s0090-8258(21)01001-5.
• A phase II evaluation of pembrolizumab in recurrent microsatellite instability-high (MSI-H) endometrial cancer patients with Lynch-like versus MLH-1 methylated characteristics (NCT02899793)Bellone S, Roque DM, Siegel ER, Buza N, Hui P, Bonazzoli E, Guglielmi A, Zammataro L, Nagarkatti N, Zaidi S, Lee J, Silasi D, Huang GS, Andikyan V, Damast S, Clark M, Azodi M, Schwartz PE, Tymon-Rosario J, Harold J, Mauricio D, Zeybek B, Menderes G, Altwerger G, Ratner E, Alexandrov LB, Iwasaki A, Kong Y, Song E, Dong W, Elvin J, Choi J, Santin AD. A phase II evaluation of pembrolizumab in recurrent microsatellite instability-high (MSI-H) endometrial cancer patients with Lynch-like versus MLH-1 methylated characteristics (NCT02899793). Annals Of Oncology 2021, 32: 1045-1046. PMID: 33932502, PMCID: PMC9465821, DOI: 10.1016/j.annonc.2021.04.013.
• Integrated mutational landscape analysis of uterine leiomyosarcomasChoi J, Manzano A, Dong W, Bellone S, Bonazzoli E, Zammataro L, Yao X, Deshpande A, Zaidi S, Guglielmi A, Gnutti B, Nagarkatti N, Tymon-Rosario JR, Harold J, Mauricio D, Zeybek B, Menderes G, Altwerger G, Jeong K, Zhao S, Buza N, Hui P, Ravaggi A, Bignotti E, Romani C, Todeschini P, Zanotti L, Odicino F, Pecorelli S, Ardighieri L, Bilguvar K, Quick CM, Silasi DA, Huang GS, Andikyan V, Clark M, Ratner E, Azodi M, Imielinski M, Schwartz PE, Alexandrov LB, Lifton RP, Schlessinger J, Santin AD. Integrated mutational landscape analysis of uterine leiomyosarcomas. Proceedings Of The National Academy Of Sciences Of The United States Of America 2021, 118: e2025182118. PMID: 33876771, PMCID: PMC8053980, DOI: 10.1073/pnas.2025182118.
• Sex Hormones, Insulin, and Insulin-like Growth Factors in Recurrence of High-Stage Endometrial CancerSex Hormones and Insulin in Endometrial Cancer RecurrenceMerritt MA, Strickler HD, Hutson AD, Einstein MH, Rohan TE, Xue X, Sherman ME, Brinton LA, Yu H, Miller DS, Ramirez NC, Lankes HA, Birrer MJ, Huang GS, Gunter MJ. Sex Hormones, Insulin, and Insulin-like Growth Factors in Recurrence of High-Stage Endometrial CancerSex Hormones and Insulin in Endometrial Cancer Recurrence. Cancer Epidemiology Biomarkers & Prevention 2021, 30: 719-726. PMID: 33622671, PMCID: PMC8026669, DOI: 10.1158/1055-9965.epi-20-1613.
• High-risk Endometrial Cancer: The Present and Future of Adjuvant TherapySoble W, Tymon-Rosario J, Huang G. High-risk Endometrial Cancer: The Present and Future of Adjuvant Therapy. Oncology & Haematology 2021, 17: 23. DOI: 10.17925/ohr.2021.17.1.23.
• Population-Based Screening for Endometrial Cancer: Human vs. Machine IntelligenceHart GR, Yan V, Huang GS, Liang Y, Nartowt BJ, Muhammad W, Deng J. Population-Based Screening for Endometrial Cancer: Human vs. Machine Intelligence. Frontiers In Artificial Intelligence 2020, 3: 539879. PMID: 33733200, PMCID: PMC7861326, DOI: 10.3389/frai.2020.539879.
• Prescribed medical cannabis in women with gynecologic malignancies: A single-institution survey-based studyWebster EM, Yadav GS, Gysler S, McNamara B, Black J, Tymon-Rosario J, Zeybek B, Han C, Arkfeld CK, Andikyan V, Menderes G, Huang G, Azodi M, Silasi DA, Santin AD, Schwartz PE, Ratner ES, Altwerger G. Prescribed medical cannabis in women with gynecologic malignancies: A single-institution survey-based study. Gynecologic Oncology Reports 2020, 34: 100667. PMID: 33204797, PMCID: PMC7653050, DOI: 10.1016/j.gore.2020.100667.
• Cervical carcinomas that overexpress human trophoblast cell-surface marker (Trop-2) are highly sensitive to the antibody-drug conjugate sacituzumab-govitecanZeybek B, Manzano A, Bianchi A, Bonazzoli E, Bellone S, Buza N, Hui P, Lopez S, Perrone E, Manara P, Zammataro L, Altwerger G, Han C, Tymon-Rosario J, Menderes G, Ratner E, Silasi D, Huang G, Azodi M, Schwartz P, Santin A. Cervical carcinomas that overexpress human trophoblast cell-surface marker (Trop-2) are highly sensitive to the antibody-drug conjugate sacituzumab-govitecan. Gynecologic Oncology 2020, 159: 177. DOI: 10.1016/j.ygyno.2020.05.265.
• Patient experience with medical marijuana in women with gynecologic malignancies: A single-institution survey-based studyWebster E, Yadav G, Gysler S, McNamara B, Black J, Tymon-Rosario J, Zeybek B, Han C, Menderes G, Huang G, Silasi D, Azodi M, Schwartz P, Santin A, Ratner E, Altwerger G. Patient experience with medical marijuana in women with gynecologic malignancies: A single-institution survey-based study. Gynecologic Oncology 2020, 159: 318. DOI: 10.1016/j.ygyno.2020.05.575.
• The PARP inhibitor niraparib demonstrates preclinical activity against HRD-deficient carcinosarcomasTymon-Rosario J, Manara P, Manzano A, Zammataro L, Bonazzoli E, Perrone E, Bellone S, Alexandrov L, Zeybek B, Han C, Altwerger G, Menderes G, Ratner E, Silasi D, Huang G, Azodi M, Schwartz P, Santin A. The PARP inhibitor niraparib demonstrates preclinical activity against HRD-deficient carcinosarcomas. Gynecologic Oncology 2020, 159: 255. DOI: 10.1016/j.ygyno.2020.05.438.
• Chemotherapy choice and impact on survival of patients with carcinosarcoma of the ovary: A retrospective reviewHosier H, Haunschild C, Altwerger G, Webster E, Buza N, Tymon-Rosario J, Zeybek B, Han C, Menderes G, Huang G, Silasi D, Azodi M, Schwartz P, Santin A, Ratner E, English D. Chemotherapy choice and impact on survival of patients with carcinosarcoma of the ovary: A retrospective review. Gynecologic Oncology 2020, 159: 124-125. DOI: 10.1016/j.ygyno.2020.05.150.
• Abstract 4851: Combination of letrozole plus abemaciclib is synergistic and suppresses tumor growth in ovarian and endometrial cancer modelsOsagie O, Li Z, Jing J, Huang G. Abstract 4851: Combination of letrozole plus abemaciclib is synergistic and suppresses tumor growth in ovarian and endometrial cancer models. Cancer Research 2020, 80: 4851-4851. DOI: 10.1158/1538-7445.am2020-4851.
• Stage III uterine serous carcinoma: modern trends in multimodality treatmentLi JY, Young MR, Huang G, Litkouhi B, Santin A, Schwartz PE, Damast S. Stage III uterine serous carcinoma: modern trends in multimodality treatment. Journal Of Gynecologic Oncology 2020, 31: e53. PMID: 32266802, PMCID: PMC7286763, DOI: 10.3802/jgo.2020.31.e53.
• Derangements in HUWE1/c-MYC pathway confer sensitivity to the BET bromodomain inhibitor GS-626510 in uterine cervical carcinomaBonazzoli E, Bellone S, Zammataro L, Gnutti B, Guglielmi A, Pelligra S, Nagarkatti N, Manara P, Tymon-Rosario J, Zeybek B, Altwerger G, Menderes G, Han C, Ratner E, Silasi DA, Huang GS, Andikyan V, Azodi M, Schwartz PE, Santin AD. Derangements in HUWE1/c-MYC pathway confer sensitivity to the BET bromodomain inhibitor GS-626510 in uterine cervical carcinoma. Gynecologic Oncology 2020, 158: 769-775. PMID: 32600791, PMCID: PMC8253557, DOI: 10.1016/j.ygyno.2020.06.484.
• Preclinical activity of sacituzumab govitecan (IMMU-132) in uterine and ovarian carcinosarcomasLopez S, Perrone E, Bellone S, Bonazzoli E, Zeybek B, Han C, Tymon-Rosario J, Altwerger G, Menderes G, Bianchi A, Zammataro L, Manzano A, Manara P, Ratner E, Silasi DA, Huang GS, Azodi M, Schwartz PE, Raspagliesi F, Angioli R, Buza N, Hui P, Bond HM, Santin AD. Preclinical activity of sacituzumab govitecan (IMMU-132) in uterine and ovarian carcinosarcomas. Oncotarget 2020, 11: 560-570. PMID: 32082489, PMCID: PMC7007291, DOI: 10.18632/oncotarget.27342.
• Cervical carcinomas that overexpress human trophoblast cell-surface marker (Trop-2) are highly sensitive to the antibody-drug conjugate sacituzumab govitecanZeybek B, Manzano A, Bianchi A, Bonazzoli E, Bellone S, Buza N, Hui P, Lopez S, Perrone E, Manara P, Zammataro L, Altwerger G, Han C, Tymon-Rosario J, Menderes G, Ratner E, Silasi DA, Huang GS, Azodi M, Schwartz PE, Santin A. Cervical carcinomas that overexpress human trophoblast cell-surface marker (Trop-2) are highly sensitive to the antibody-drug conjugate sacituzumab govitecan. Scientific Reports 2020, 10: 973. PMID: 31969666, PMCID: PMC6976591, DOI: 10.1038/s41598-020-58009-3.
• Sacituzumab govitecan, an antibody‐drug conjugate targeting trophoblast cell‐surface antigen 2, shows cytotoxic activity against poorly differentiated endometrial adenocarcinomas in vitro and in vivoPerrone E, Manara P, Lopez S, Bellone S, Bonazzoli E, Manzano A, Zammataro L, Bianchi A, Zeybek B, Buza N, Tymon‐Rosario J, Altwerger G, Han C, Menderes G, Huang GS, Ratner E, Silasi D, Azodi M, Hui P, Schwartz PE, Scambia G, Santin AD. Sacituzumab govitecan, an antibody‐drug conjugate targeting trophoblast cell‐surface antigen 2, shows cytotoxic activity against poorly differentiated endometrial adenocarcinomas in vitro and in vivo. Molecular Oncology 2020, 14: 645-656. PMID: 31891442, PMCID: PMC7053235, DOI: 10.1002/1878-0261.12627.
• In vitro and in vivo activity of sacituzumab govitecan, an antibody-drug conjugate targeting trophoblast cell-surface antigen 2 (Trop-2) in uterine serous carcinomaHan C, Perrone E, Zeybek B, Bellone S, Tymon-Rosario J, Altwerger G, Menderes G, Feinberg J, Haines K, Muller Karger ME, Bianchi A, Zammataro L, Manzano A, Bonazzoli E, Manara P, Buza N, Hui P, Ratner E, Silasi DA, Huang GS, Azodi M, Schwartz PE, Lopez S, Santin AD. In vitro and in vivo activity of sacituzumab govitecan, an antibody-drug conjugate targeting trophoblast cell-surface antigen 2 (Trop-2) in uterine serous carcinoma. Gynecologic Oncology 2019, 156: 430-438. PMID: 31839338, DOI: 10.1016/j.ygyno.2019.11.018.
• Whole-exome sequencing of cervical carcinomas identifies activating ERBB2 and PIK3CA mutations as targets for combination therapyZammataro L, Lopez S, Bellone S, Pettinella F, Bonazzoli E, Perrone E, Zhao S, Menderes G, Altwerger G, Han C, Zeybek B, Bianchi A, Manzano A, Manara P, Cocco E, Buza N, Hui P, Wong S, Ravaggi A, Bignotti E, Romani C, Todeschini P, Zanotti L, Odicino F, Pecorelli S, Donzelli C, Ardighieri L, Angioli R, Raspagliesi F, Scambia G, Choi J, Dong W, Bilguvar K, Alexandrov LB, Silasi DA, Huang GS, Ratner E, Azodi M, Schwartz PE, Pirazzoli V, Stiegler AL, Boggon TJ, Lifton RP, Schlessinger J, Santin AD. Whole-exome sequencing of cervical carcinomas identifies activating ERBB2 and PIK3CA mutations as targets for combination therapy. Proceedings Of The National Academy Of Sciences Of The United States Of America 2019, 116: 22730-22736. PMID: 31624127, PMCID: PMC6842590, DOI: 10.1073/pnas.1911385116.
• Endometrial Cancer Risk Prediction and Stratification Using Personal Health DataHart G, Nartowt B, Muhammad W, Liang Y, Huang G, Deng J. Endometrial Cancer Risk Prediction and Stratification Using Personal Health Data. International Journal Of Radiation Oncology • Biology • Physics 2019, 105: e134-e135. DOI: 10.1016/j.ijrobp.2019.06.2170.
• Stage III Uterine Serous Carcinoma: Improved Outcomes in the Modern Era with Multi-Modality TreatmentLi J, Young M, Huang G, Litkouhi B, Santin A, Schwartz P, Damast S. Stage III Uterine Serous Carcinoma: Improved Outcomes in the Modern Era with Multi-Modality Treatment. International Journal Of Radiation Oncology • Biology • Physics 2019, 105: s225. DOI: 10.1016/j.ijrobp.2019.06.318.
• PARP-1 activity (PAR) determines the sensitivity of cervical cancer to olaparibBianchi A, Lopez S, Altwerger G, Bellone S, Bonazzoli E, Zammataro L, Manzano A, Manara P, Perrone E, Zeybek B, Han C, Menderes G, Ratner E, Silasi DA, Huang GS, Azodi M, Newberg JY, Pavlick DC, Elvin J, Frampton GM, Schwartz PE, Santin AD. PARP-1 activity (PAR) determines the sensitivity of cervical cancer to olaparib. Gynecologic Oncology 2019, 155: 144-150. PMID: 31434613, PMCID: PMC6788971, DOI: 10.1016/j.ygyno.2019.08.010.
• Precision Therapy for Aggressive Endometrial Cancer by Reactivation of Protein Phosphatase 2AHaines K, Huang GS. Precision Therapy for Aggressive Endometrial Cancer by Reactivation of Protein Phosphatase 2A. Cancer Research 2019, 79: 4009-4010. PMID: 31416848, DOI: 10.1158/0008-5472.can-19-1938.
• Neutrophilia and mortality in women with uterine carcinosarcomaArend R, Van Arsdale A, Gojayev A, Roane BM, Doo D, Leath C, Goldberg GL, Huang G. Neutrophilia and mortality in women with uterine carcinosarcoma. International Journal Of Gynecological Cancer 2019, 29: 1258. PMID: 31320488, DOI: 10.1136/ijgc-2019-000440.
• Stratifying Ovarian Cancer Risk Using Personal Health DataHart GR, Nartowt BJ, Muhammad W, Liang Y, Huang GS, Deng J. Stratifying Ovarian Cancer Risk Using Personal Health Data. Frontiers In Big Data 2019, 2: 24. PMID: 33693347, PMCID: PMC7931902, DOI: 10.3389/fdata.2019.00024.
• Sacituzumab govitecan (IMMU-132) in uterine serous carcinomaHan C, Bianchi A, Bellone S, Altwerger G, Menderes G, Zeybek B, Haines K, Lopez S, Azodi M, Litkouhi B, Silasi D, Huang G, Ratner E, Schwartz P, Santin A. Sacituzumab govitecan (IMMU-132) in uterine serous carcinoma. Gynecologic Oncology 2019, 154: 64. DOI: 10.1016/j.ygyno.2019.04.152.
• Primary cytoreductive surgery versus neoadjuvant chemotherapy for advanced-stage uterine malignanciesAltwerger G, Haines K, Yadav G, McNamara B, Hosier H, Menderes G, Huang G, Azodi M, Silasi D, Santin A, Ratner E, Schwartz P, Litkouhi B. Primary cytoreductive surgery versus neoadjuvant chemotherapy for advanced-stage uterine malignancies. Gynecologic Oncology 2019, 154: 243. DOI: 10.1016/j.ygyno.2019.04.561.
• The combination of olaparib (Poly ADP-ribose polymerase inhibitor) with neratinib (pan-HER inhibitor) is synergistic in epithelial ovarian carcinoma overexpressing HER2.Han C, Altwerger G, Menderes G, Bellone S, Bianchi A, Yadav G, Lopez S, Manzano A, Ratner E, Azodi M, Litkouhi B, Silasi D, Huang G, Schwartz P, Santin A. The combination of olaparib (Poly ADP-ribose polymerase inhibitor) with neratinib (pan-HER inhibitor) is synergistic in epithelial ovarian carcinoma overexpressing HER2. Gynecologic Oncology 2019, 154: 35. DOI: 10.1016/j.ygyno.2019.04.084.
• Impact of carboplatin hypersensitivity and desensitization on overall survival in patients with recurrent ovarian cancerAltwerger G, Han C, Zeybek B, Haines K, Gressel G, Huang G, Litkouhi B, Azodi M, Silasi D, Santin A, Schwartz P, Ratner E. Impact of carboplatin hypersensitivity and desensitization on overall survival in patients with recurrent ovarian cancer. Gynecologic Oncology 2019, 154: 28-29. DOI: 10.1016/j.ygyno.2019.04.069.
• Sex hormone, insulin, and insulin-like growth factor signaling in recurrence of high stage endometrial cancer: Results from the NRG Oncology/Gynecologic Oncology Group 210 trial.Huang G, Merritt M, Hutson A, Strickler H, Einstein M, Brouwer-Visser J, Ramirez N, Lankes H, El-Bahrawy M, Xue X, Yu H, Mannel R, O'Malley D, Mutch D, Disilvestro P, Geller M, Guntupalli S, Birrer M, Miller D, Gunter M. Sex hormone, insulin, and insulin-like growth factor signaling in recurrence of high stage endometrial cancer: Results from the NRG Oncology/Gynecologic Oncology Group 210 trial. Journal Of Clinical Oncology 2019, 37: 5509-5509. DOI: 10.1200/jco.2019.37.15_suppl.5509.
• ARID1A interacts with nonmuscle myosin IIA to regulate cancer cell motility.Osagie O, Li Z, Mi S, Aguilan J, Huang G. ARID1A interacts with nonmuscle myosin IIA to regulate cancer cell motility. Journal Of Clinical Oncology 2019, 37: e17036-e17036. DOI: 10.1200/jco.2019.37.15_suppl.e17036.
• PI3K oncogenic mutations mediate resistance to afatinib in HER2/neu overexpressing gynecological cancersBonazzoli E, Cocco E, Lopez S, Bellone S, Zammataro L, Bianchi A, Manzano A, Yadav G, Manara P, Perrone E, Haines K, Espinal M, Dugan K, Menderes G, Altwerger G, Han C, Zeybek B, Litkouhi B, Ratner E, Silasi DA, Huang GS, Azodi M, Schwartz PE, Santin AD. PI3K oncogenic mutations mediate resistance to afatinib in HER2/neu overexpressing gynecological cancers. Gynecologic Oncology 2019, 153: 158-164. PMID: 30630630, PMCID: PMC6430698, DOI: 10.1016/j.ygyno.2019.01.002.
• Mutational landscape of primary, metastatic, and recurrent ovarian cancer reveals c-MYC gains as potential target for BET inhibitorsLi C, Bonazzoli E, Bellone S, Choi J, Dong W, Menderes G, Altwerger G, Han C, Manzano A, Bianchi A, Pettinella F, Manara P, Lopez S, Yadav G, Riccio F, Zammataro L, Zeybek B, Yang-Hartwich Y, Buza N, Hui P, Wong S, Ravaggi A, Bignotti E, Romani C, Todeschini P, Zanotti L, Zizioli V, Odicino F, Pecorelli S, Ardighieri L, Silasi DA, Litkouhi B, Ratner E, Azodi M, Huang GS, Schwartz PE, Lifton RP, Schlessinger J, Santin AD. Mutational landscape of primary, metastatic, and recurrent ovarian cancer reveals c-MYC gains as potential target for BET inhibitors. Proceedings Of The National Academy Of Sciences Of The United States Of America 2018, 116: 619-624. PMID: 30584090, PMCID: PMC6329978, DOI: 10.1073/pnas.1814027116.
• Inhibition of BET Bromodomain Proteins with GS-5829 and GS-626510 in Uterine Serous Carcinoma, a Biologically Aggressive Variant of Endometrial CancerBonazzoli E, Predolini F, Cocco E, Bellone S, Altwerger G, Menderes G, Zammataro L, Bianchi A, Pettinella F, Riccio F, Han C, Yadav G, Lopez S, Manzano A, Manara P, Buza N, Hui P, Wong S, Litkouhi B, Ratner E, Silasi DA, Huang GS, Azodi M, Schwartz PE, Schlessinger J, Santin AD. Inhibition of BET Bromodomain Proteins with GS-5829 and GS-626510 in Uterine Serous Carcinoma, a Biologically Aggressive Variant of Endometrial Cancer. Clinical Cancer Research 2018, 24: 4845-4853. PMID: 29941483, PMCID: PMC6168417, DOI: 10.1158/1078-0432.ccr-18-0864.
• Impact of carboplatin hypersensitivity and desensitization on patients with recurrent ovarian cancerAltwerger G, Florsheim EB, Menderes G, Black J, Schwab C, Gressel GM, Nelson WK, Carusillo N, Passante T, Huang G, Litkouhi B, Azodi M, Silasi DA, Santin A, Schwartz PE, Ratner ES. Impact of carboplatin hypersensitivity and desensitization on patients with recurrent ovarian cancer. Journal Of Cancer Research And Clinical Oncology 2018, 144: 2449-2456. PMID: 30255380, DOI: 10.1007/s00432-018-2753-y.
• Remarkable in vitro and in vivo activity of IMGN853, an antibody-drug conjugate targeting folate receptor alpha linked to the tubulin-disrupting maytansinoid DM4, in biologically aggressive (type II) endometrial cancersAltwerger G, Bonazzoli E, Bellone S, Takata T, Menderes G, Pettinella F, Bianchi A, Riccio F, Feinberg J, Zammataro L, Han C, Yadav G, Dugan K, Morneault A, Ponte J, Buza N, Hui P, Litkouhi B, Ratner E, Silasi D, Huang G, Azodi M, Schwartz P, Santin A. Remarkable in vitro and in vivo activity of IMGN853, an antibody-drug conjugate targeting folate receptor alpha linked to the tubulin-disrupting maytansinoid DM4, in biologically aggressive (type II) endometrial cancers. Gynecologic Oncology 2018, 149: 70. DOI: 10.1016/j.ygyno.2018.04.159.
• In vitro and in vivo activity of IMGN853, an Antibody-Drug Conjugate targeting Folate Receptor Alpha linked to DM4, in biologically aggressive endometrial cancersAltwerger G, Bonazzoli E, Bellone S, Egawa-Takata T, Menderes G, Pettinella F, Bianchi A, Riccio F, Feinberg J, Zammataro L, Han C, Yadav G, Dugan K, Morneault A, Ponte JF, Buza N, Hui P, Wong S, Litkouhi B, Ratner E, Silasi DA, Huang GS, Azodi M, Schwartz PE, Santin AD. In vitro and in vivo activity of IMGN853, an Antibody-Drug Conjugate targeting Folate Receptor Alpha linked to DM4, in biologically aggressive endometrial cancers. Molecular Cancer Therapeutics 2018, 17: molcanther.0930.2017. PMID: 29440294, PMCID: PMC5932245, DOI: 10.1158/1535-7163.mct-17-0930.
• A novel multiple biomarker panel for the early detection of high-grade serous ovarian carcinomaHan C, Bellone S, Siegel ER, Altwerger G, Menderes G, Bonazzoli E, Egawa-Takata T, Pettinella F, Bianchi A, Riccio F, Zammataro L, Yadav G, Marto JA, Penet MF, Levine DA, Drapkin R, Patel A, Litkouhi B, Ratner E, Silasi DA, Huang GS, Azodi M, Schwartz PE, Santin AD. A novel multiple biomarker panel for the early detection of high-grade serous ovarian carcinoma. Gynecologic Oncology 2018, 149: 585-591. PMID: 29572027, PMCID: PMC5986604, DOI: 10.1016/j.ygyno.2018.03.050.
• Evaluation of a Streamlined Oncologist-Led BRCA Mutation Testing and Counseling Model for Patients With Ovarian Cancer.Colombo N, Huang G, Scambia G, Chalas E, Pignata S, Fiorica J, Van Le L, Ghamande S, González-Santiago S, Bover I, Graña Suárez B, Green A, Huot-Marchand P, Bourhis Y, Karve S, Blakeley C. Evaluation of a Streamlined Oncologist-Led BRCA Mutation Testing and Counseling Model for Patients With Ovarian Cancer. Journal Of Clinical Oncology 2018, 36: 1300-1307. PMID: 29558274, PMCID: PMC6804908, DOI: 10.1200/jco.2017.76.2781.
• Female Sex Hormone Receptor Profiling in Uterine AdenosarcomasMarcus JZ, Klobocista M, Karabakhtsian RG, Prossnitz E, Goldberg GL, Huang GS. Female Sex Hormone Receptor Profiling in Uterine Adenosarcomas. International Journal Of Gynecological Cancer 2018, 28: 500-504. PMID: 29303935, PMCID: PMC6125779, DOI: 10.1097/igc.0000000000001183.
• Insulin‐like growth factor 2: a poor prognostic biomarker linked to racial disparity in women with uterine carcinosarcomaVan Arsdale AR, Arend RC, Cossio MJ, Erickson BK, Wang Y, Doo DW, Leath CA, Goldberg GL, Huang GS. Insulin‐like growth factor 2: a poor prognostic biomarker linked to racial disparity in women with uterine carcinosarcoma. Cancer Medicine 2018, 7: 616-625. PMID: 29455465, PMCID: PMC5852335, DOI: 10.1002/cam4.1335.
• Superior in vitro and in vivo activity of trastuzumab-emtansine (T-DM1) in comparison to trastuzumab, pertuzumab and their combination in epithelial ovarian carcinoma with high HER2/neu expressionMenderes G, Bonazzoli E, Bellone S, Altwerger G, Black JD, Dugan K, Pettinella F, Masserdotti A, Riccio F, Bianchi A, Zammataro L, de Haydu C, Buza N, Hui P, Wong S, Huang GS, Litkouhi B, Ratner E, Silasi DA, Azodi M, Schwartz PE, Santin AD. Superior in vitro and in vivo activity of trastuzumab-emtansine (T-DM1) in comparison to trastuzumab, pertuzumab and their combination in epithelial ovarian carcinoma with high HER2/neu expression. Gynecologic Oncology 2017, 147: 145-152. PMID: 28705408, PMCID: PMC5605415, DOI: 10.1016/j.ygyno.2017.07.009.
• Assessment of BRCA testing uptake in ovarian cancer patients during the implementation of an oncologist-led genetic counseling model at an urban and suburban teaching hospital.Jorgensen J, Chiu K, Gotimer K, Chalas E, Kuo D, Huang G. Assessment of BRCA testing uptake in ovarian cancer patients during the implementation of an oncologist-led genetic counseling model at an urban and suburban teaching hospital. Journal Of Clinical Oncology 2017, 35: 1589-1589. DOI: 10.1200/jco.2017.35.15_suppl.1589.
• ENGAGE: Evaluation of a streamlined oncologist-led BRCA mutation ( BRCA m) testing and counselling model for patients with ovarian cancer.Colombo N, Scambia G, Chalas E, Huang G, Pignata S, Fiorica J, Van Le L, Ghamande S, Gonzalez Santiago S, Bover I, Suárez B, Green A, Huot-Marchand P, Bourhis Y, Karve S, Blakeley C. ENGAGE: Evaluation of a streamlined oncologist-led BRCA mutation ( BRCA m) testing and counselling model for patients with ovarian cancer. Journal Of Clinical Oncology 2017, 35: 5559-5559. DOI: 10.1200/jco.2017.35.15_suppl.5559.
• Genetic landscape of clear cell endometrial cancer and the era of precision medicineHuang GS, Santin AD. Genetic landscape of clear cell endometrial cancer and the era of precision medicine. Cancer 2017, 123: 3216-3218. PMID: 28485840, PMCID: PMC5907932, DOI: 10.1002/cncr.30743.
• SYD985, a novel duocarmycin-based HER2-targeting antibody-drug conjugate, shows promising antitumor activity in epithelial ovarian carcinoma with HER2/Neu expressionMenderes G, Bonazzoli E, Bellone S, Black J, Altwerger G, Masserdotti A, Pettinella F, Zammataro L, Buza N, Hui P, Wong S, Litkouhi B, Ratner E, Silasi DA, Huang GS, Azodi M, Schwartz PE, Santin AD. SYD985, a novel duocarmycin-based HER2-targeting antibody-drug conjugate, shows promising antitumor activity in epithelial ovarian carcinoma with HER2/Neu expression. Gynecologic Oncology 2017, 146: 179-186. PMID: 28473206, PMCID: PMC5533304, DOI: 10.1016/j.ygyno.2017.04.023.
• LBA34 A novel oncologist-led BRCA1/2 germline mutation (gBRCAm) testing and counselling model for patients with ovarian cancer: Interim results from the ENGAGE (NCT02406235) studyScambia G, Chalas E, Huang G, Suárez B, González-Santiago S, Colombo N, Pignata S, Huot-Marchand P, Karve S, Blakeley C. LBA34 A novel oncologist-led BRCA1/2 germline mutation (gBRCAm) testing and counselling model for patients with ovarian cancer: Interim results from the ENGAGE (NCT02406235) study. Annals Of Oncology 2016, 27: vi569. DOI: 10.1093/annonc/mdw435.28.
• RNA-seq Identification of RACGAP1 as a Metastatic Driver in Uterine CarcinosarcomaMi S, Lin M, Brouwer-Visser J, Heim J, Smotkin D, Hebert T, Gunter MJ, Goldberg GL, Zheng D, Huang GS. RNA-seq Identification of RACGAP1 as a Metastatic Driver in Uterine Carcinosarcoma. Clinical Cancer Research 2016, 22: 4676-4686. PMID: 27121792, DOI: 10.1158/1078-0432.ccr-15-2116.
• Endometrial expression of hormonal and insulin/IGF receptors in relation to cancer risk factorsMerritt M, Strickler H, Einstein M, Cossio M, Whitney K, Gunter M, Huang G. Endometrial expression of hormonal and insulin/IGF receptors in relation to cancer risk factors. Gynecologic Oncology 2016, 141: 172-173. DOI: 10.1016/j.ygyno.2016.04.449.
• Evaluating a novel oncologist-led BRCA1/2 mutation ( BRCA m) testing counseling model for patients with ovarian cancer: Interim results from the ENGAGE study.Huang G, Tchakov I, Bourhis Y, Scambia G, Capoluongo E, Grana-Suarez B, Lopez-Guerrero J, Poveda A, Karve S, Potter D, Lawrence D, Tyczynski J, Chalas E. Evaluating a novel oncologist-led BRCA1/2 mutation ( BRCA m) testing counseling model for patients with ovarian cancer: Interim results from the ENGAGE study. Journal Of Clinical Oncology 2016, 34: e17048-e17048. DOI: 10.1200/jco.2016.34.15_suppl.e17048.
• Evaluation of circulating neutrophils as a biomarker for outcomes in uterine carcinosarcoma.Van Arsdale A, Arend R, Mitchell C, Gilbert A, Leath C, Huang G. Evaluation of circulating neutrophils as a biomarker for outcomes in uterine carcinosarcoma. Journal Of Clinical Oncology 2016, 34: e17121-e17121. DOI: 10.1200/jco.2016.34.15_suppl.e17121.
• Insulin/IGF and sex hormone axes in human endometrium and associations with endometrial cancer risk factorsMerritt MA, Strickler HD, Einstein MH, Yang HP, Sherman ME, Wentzensen N, Brouwer-Visser J, Cossio MJ, Whitney KD, Yu H, Gunter MJ, Huang GS. Insulin/IGF and sex hormone axes in human endometrium and associations with endometrial cancer risk factors. Cancer Causes & Control 2016, 27: 737-748. PMID: 27125830, PMCID: PMC4870288, DOI: 10.1007/s10552-016-0751-4.
• Retreatment with aromatase inhibitor therapy in the management of granulosa cell tumorSchwartz M, Huang GS. Retreatment with aromatase inhibitor therapy in the management of granulosa cell tumor. Gynecologic Oncology Reports 2015, 15: 20-21. PMID: 26937482, PMCID: PMC4750011, DOI: 10.1016/j.gore.2015.12.004.
• Designing a broad-spectrum integrative approach for cancer prevention and treatmentBlock KI, Gyllenhaal C, Lowe L, Amedei A, Amin AR, Amin A, Aquilano K, Arbiser J, Arreola A, Arzumanyan A, Ashraf SS, Azmi AS, Benencia F, Bhakta D, Bilsland A, Bishayee A, Blain SW, Block PB, Boosani CS, Carey TE, Carnero A, Carotenuto M, Casey SC, Chakrabarti M, Chaturvedi R, Chen GZ, Chen H, Chen S, Chen YC, Choi BK, Ciriolo MR, Coley HM, Collins AR, Connell M, Crawford S, Curran CS, Dabrosin C, Damia G, Dasgupta S, DeBerardinis RJ, Decker WK, Dhawan P, Diehl AM, Dong JT, Dou QP, Drew JE, Elkord E, El-Rayes B, Feitelson MA, Felsher DW, Ferguson LR, Fimognari C, Firestone GL, Frezza C, Fujii H, Fuster MM, Generali D, Georgakilas AG, Gieseler F, Gilbertson M, Green MF, Grue B, Guha G, Halicka D, Helferich WG, Heneberg P, Hentosh P, Hirschey MD, Hofseth LJ, Holcombe RF, Honoki K, Hsu HY, Huang GS, Jensen LD, Jiang WG, Jones LW, Karpowicz PA, Keith WN, Kerkar SP, Khan GN, Khatami M, Ko YH, Kucuk O, Kulathinal RJ, Kumar NB, Kwon BS, Le A, Lea MA, Lee HY, Lichtor T, Lin LT, Locasale JW, Lokeshwar BL, Longo VD, Lyssiotis CA, MacKenzie KL, Malhotra M, Marino M, Martinez-Chantar ML, Matheu A, Maxwell C, McDonnell E, Meeker AK, Mehrmohamadi M, Mehta K, Michelotti GA, Mohammad RM, Mohammed SI, Morre DJ, Muralidhar V, Muqbil I, Murphy MP, Nagaraju GP, Nahta R, Niccolai E, Nowsheen S, Panis C, Pantano F, Parslow VR, Pawelec G, Pedersen PL, Poore B, Poudyal D, Prakash S, Prince M, Raffaghello L, Rathmell JC, Rathmell WK, Ray SK, Reichrath J, Rezazadeh S, Ribatti D, Ricciardiello L, Robey RB, Rodier F, Rupasinghe HP, Russo GL, Ryan EP, Samadi AK, Sanchez-Garcia I, Sanders AJ, Santini D, Sarkar M, Sasada T, Saxena NK, Shackelford RE, Kumara H, Sharma D, Shin DM, Sidransky D, Siegelin MD, Signori E, Singh N, Sivanand S, Sliva D, Smythe C, Spagnuolo C, Stafforini DM, Stagg J, Subbarayan PR, Sundin T, Talib WH, Thompson SK, Tran PT, Ungefroren H, Heiden M, Venkateswaran V, Vinay DS, Vlachostergios PJ, Wang Z, Wellen KE, Whelan RL, Yang ES, Yang H, Yang X, Yaswen P, Yedjou C, Yin X, Zhu J, Zollo M. Designing a broad-spectrum integrative approach for cancer prevention and treatment. Seminars In Cancer Biology 2015, 35: s276-s304. PMID: 26590477, PMCID: PMC4819002, DOI: 10.1016/j.semcancer.2015.09.007.
• PTEN expression in benign human endometrial tissue and cancer in relation to endometrial cancer risk factorsYang HP, Meeker A, Guido R, Gunter MJ, Huang GS, Luhn P, d’Ambrosio L, Wentzensen N, Sherman ME. PTEN expression in benign human endometrial tissue and cancer in relation to endometrial cancer risk factors. Cancer Causes & Control 2015, 26: 1729-1736. PMID: 26376893, PMCID: PMC4628559, DOI: 10.1007/s10552-015-0666-5.
• Abstract 5131: Establishment of uterine carcinosarcoma primary cell lines for chemosensitivity testing and evaluation of targeted therapyBrouwer-Visser J, Scott E, Mi S, Cossio M, Hebert T, Huang G. Abstract 5131: Establishment of uterine carcinosarcoma primary cell lines for chemosensitivity testing and evaluation of targeted therapy. 2015, 5131-5131. DOI: 10.1158/1538-7445.am2015-5131.
• Abstract 5257: Immunohistochemical analysis and comprehensive hormone receptor profiling of uterine adenosarcomas at a single institutionZechmeister J, Huang G, Karabakhtsian R, Schwartz M, Prossnitz E, Goldberg G, Klobocista M. Abstract 5257: Immunohistochemical analysis and comprehensive hormone receptor profiling of uterine adenosarcomas at a single institution. 2015, 5257-5257. DOI: 10.1158/1538-7445.am2015-5257.
• Evaluation of a novel combination treatment strategy using patient-derived xenografts of uterine carcinosarcomaBrouwer-Visser J, Mi S, Cossio M, Schwartz M, Hebert T, Zou Y, Kuo D, Huang G. Evaluation of a novel combination treatment strategy using patient-derived xenografts of uterine carcinosarcoma. Gynecologic Oncology 2015, 137: 201-202. DOI: 10.1016/j.ygyno.2015.01.506.
• Evaluation of insulin-like growth factor 2 as a biomarker in uterine carcinosarcomaCossio M, Arend R, Van Arsdale A, Erickson B, Wang Y, Doo D, Leath C, Goldberg G, Huang G. Evaluation of insulin-like growth factor 2 as a biomarker in uterine carcinosarcoma. Gynecologic Oncology 2015, 137: 60-61. DOI: 10.1016/j.ygyno.2015.01.141.
• The impact of obesity on prostate cancer recurrence observed after exclusion of diabeticsAgalliu I, Williams S, Adler B, Androga L, Siev M, Lin J, Xue X, Huang G, Strickler HD, Ghavamian R. The impact of obesity on prostate cancer recurrence observed after exclusion of diabetics. Cancer Causes & Control 2015, 26: 821-830. PMID: 25771797, PMCID: PMC4984400, DOI: 10.1007/s10552-015-0554-z.
• Evasion of anti-growth signaling: A key step in tumorigenesis and potential target for treatment and prophylaxis by natural compoundsAmin ARMR, Karpowicz PA, Carey TE, Arbiser J, Nahta R, Chen ZG, Dong JT, Kucuk O, Khan GN, Huang GS, Mi S, Lee HY, Reichrath J, Honoki K, Georgakilas AG, Amedei A, Amin A, Helferich B, Boosani CS, Ciriolo MR, Chen S, Mohammed SI, Azmi AS, Keith WN, Bhakta D, Halicka D, Niccolai E, Fujii H, Aquilano K, Ashraf SS, Nowsheen S, Yang X, Bilsland A, Shin DM. Evasion of anti-growth signaling: A key step in tumorigenesis and potential target for treatment and prophylaxis by natural compounds. Seminars In Cancer Biology 2015, 35: s55-s77. PMID: 25749195, PMCID: PMC4561219, DOI: 10.1016/j.semcancer.2015.02.005.
• IGF2 signaling and regulation in cancerBrouwer-Visser J, Huang GS. IGF2 signaling and regulation in cancer. Cytokine & Growth Factor Reviews 2015, 26: 371-377. PMID: 25704323, DOI: 10.1016/j.cytogfr.2015.01.002.
• Transforming Growth Factor &bgr;1 and Extracellular Matrix Protease Expression in the Uterosacral Ligaments of Patients With and Without Pelvic Organ ProlapseLeegant A, Zuckerwise LC, Downing K, Brouwer-Visser J, Zhu C, Cossio MJ, Strube F, Xie X, Banks E, Huang GS. Transforming Growth Factor &bgr;1 and Extracellular Matrix Protease Expression in the Uterosacral Ligaments of Patients With and Without Pelvic Organ Prolapse. Urogynecology 2015, 21: 53-58. PMID: 25185601, PMCID: PMC4344824, DOI: 10.1097/spv.0000000000000130.
• Insulin-Like Growth Factor 2 Silencing Restores Taxol Sensitivity in Drug Resistant Ovarian CancerBrouwer-Visser J, Lee J, McCullagh K, Cossio MJ, Wang Y, Huang GS. Insulin-Like Growth Factor 2 Silencing Restores Taxol Sensitivity in Drug Resistant Ovarian Cancer. PLOS ONE 2014, 9: e100165. PMID: 24932685, PMCID: PMC4059749, DOI: 10.1371/journal.pone.0100165.
• Subcellular localization and function of insulin-like growth factor 2 (IGF2) in uterine carcinosarcomaHeim J, Mi S, Cossio-Poblete M, Brouwer-Visser J, Wang Y, Gunter M, Huang G. Subcellular localization and function of insulin-like growth factor 2 (IGF2) in uterine carcinosarcoma. Gynecologic Oncology 2014, 133: 111. DOI: 10.1016/j.ygyno.2014.03.295.
• Expression of GPER, ERβ, ERα, and PR in gynecologic sarcomasKlobocista M, Phaeton R, Burton E, Van Arsdale A, Hebert T, Smith H, Arias-Pulido H, Prossnitz E, Goldberg G, Huang G. Expression of GPER, ERβ, ERα, and PR in gynecologic sarcomas. Gynecologic Oncology 2014, 133: 114. DOI: 10.1016/j.ygyno.2014.03.301.
• ER-alpha, PR, EGFR and GPER expression differentially correlate with survival in endometrial carcinomaSmith H, Qualls C, Huang G, Arias-Pulido H, Howard T, Joste N, Van Arsdale A, Prossnitz E. ER-alpha, PR, EGFR and GPER expression differentially correlate with survival in endometrial carcinoma. Gynecologic Oncology 2013, 130: e86. DOI: 10.1016/j.ygyno.2013.04.260.
• Predictors and incidence of radical vulvectomy complications in the modern era: A National Surgical Quality Improvement Program studyLin J, Yu M, Beriwal S, Krivak T, Huang G, Sukumvanich P. Predictors and incidence of radical vulvectomy complications in the modern era: A National Surgical Quality Improvement Program study. Gynecologic Oncology 2013, 130: e38. DOI: 10.1016/j.ygyno.2013.04.148.
• RACGAP1 overexpression in uterine carcinosarcomas.Mi S, Lin M, Heim J, Isani S, Brouwer-Visser J, Cossio-Poblete M, Smotkin D, Gunter M, Zheng D, Huang G. RACGAP1 overexpression in uterine carcinosarcomas. Journal Of Clinical Oncology 2013, 31: e22009-e22009. DOI: 10.1200/jco.2013.31.15_suppl.e22009.
• Abstract 948: In vivo evaluation of IGF2 RNA interference in a mouse xenograft model of paclitaxel-resistant human ovarian cancer.Brouwer-Visser J, Lee J, Cossio M, Huang G. Abstract 948: In vivo evaluation of IGF2 RNA interference in a mouse xenograft model of paclitaxel-resistant human ovarian cancer. Cancer Research 2013, 73: 948-948. DOI: 10.1158/1538-7445.am2013-948.
• Abstract 1080: Effect of IGF2 overexpression on the tumorigenicity of human ovarian carcinoma cellsBrouwer-Visser J, Cossio M, Chao S, Huang G. Abstract 1080: Effect of IGF2 overexpression on the tumorigenicity of human ovarian carcinoma cells. Cancer Research 2012, 72: 1080-1080. DOI: 10.1158/1538-7445.am2012-1080.
• Modulation of drug resistance in ovarian carcinoma cells by insulin-like growth factor-2 RNA interferenceBrouwer-Visser J, Lee J, Huang G. Modulation of drug resistance in ovarian carcinoma cells by insulin-like growth factor-2 RNA interference. Gynecologic Oncology 2012, 125: s135. DOI: 10.1016/j.ygyno.2011.12.330.
• Phase II trial of adjuvant pelvic radiation “sandwiched” between ifosfamide or ifosfamide plus cisplatin in women with uterine carcinosarcomaEinstein MH, Klobocista M, Hou JY, Lee S, Mutyala S, Mehta K, Reimers LL, Kuo D, Huang GS, Goldberg GL. Phase II trial of adjuvant pelvic radiation “sandwiched” between ifosfamide or ifosfamide plus cisplatin in women with uterine carcinosarcoma. Gynecologic Oncology 2011, 124: 26-30. PMID: 22055846, PMCID: PMC3787514, DOI: 10.1016/j.ygyno.2011.10.008.
• Clinical utility of chromogranin A and octerotide in large cell neuro endocrine carcinoma of the uterine corpusShahabi S, Pellicciotta I, Hou J, Graceffa S, Huang GS, Samuelson RN, Goldberg GL. Clinical utility of chromogranin A and octerotide in large cell neuro endocrine carcinoma of the uterine corpus. Rare Tumors 2011, 3: 41. PMID: 22355496, PMCID: PMC3282446, DOI: 10.4081/rt.2011.e41.
• Phase II trial of adjuvant pelvic radiation “sandwiched” between combination paclitaxel and carboplatin in women with uterine papillary serous carcinomaEinstein MH, Frimer M, Kuo D, Reimers LL, Mehta K, Mutyala S, Huang GS, Hou JY, Goldberg GL. Phase II trial of adjuvant pelvic radiation “sandwiched” between combination paclitaxel and carboplatin in women with uterine papillary serous carcinoma. Gynecologic Oncology 2011, 124: 21-25. PMID: 22035806, PMCID: PMC3681611, DOI: 10.1016/j.ygyno.2011.10.007.
• Abstract A48: Effect of constitutive IGF2 overexpression on tumorigenicity of human ovarian carcinoma cellsBrouwer-Visser J, Chao S, Huang G. Abstract A48: Effect of constitutive IGF2 overexpression on tumorigenicity of human ovarian carcinoma cells. Cancer Research 2011, 71: a48-a48. DOI: 10.1158/1538-7445.fbcr11-a48.
• Downregulation of Filamin A Interacting Protein 1-Like is Associated with Promoter Methylation and Induces an Invasive Phenotype in Ovarian CancerBurton ER, Gaffar A, Lee SJ, Adeshuko F, Whitney KD, Chung JY, Hewitt SM, Huang GS, Goldberg GL, Libutti SK, Kwon M. Downregulation of Filamin A Interacting Protein 1-Like is Associated with Promoter Methylation and Induces an Invasive Phenotype in Ovarian Cancer. Molecular Cancer Research 2011, 9: 1126-1138. PMID: 21693594, PMCID: PMC3157597, DOI: 10.1158/1541-7786.mcr-11-0162.
• Performance of Serum CA125 as a Prognostic Biomarker in Patients With Uterine Papillary Serous CarcinomaGupta D, Gunter MJ, Yang K, Lee S, Zuckerwise L, Chen LM, Goldberg GL, Huang GS. Performance of Serum CA125 as a Prognostic Biomarker in Patients With Uterine Papillary Serous Carcinoma. International Journal Of Gynecological Cancer 2011, 21: 529-534. PMID: 21436701, DOI: 10.1097/igc.0b013e31821091b5.
• Tumor expression of the type I insulin-like growth factor receptor is an independent prognostic factor in epithelial ovarian cancerHuang G, Hebert T, Kim C, Lin J, Arias-Pulido H, Smith H. Tumor expression of the type I insulin-like growth factor receptor is an independent prognostic factor in epithelial ovarian cancer. Gynecologic Oncology 2011, 120: s58. DOI: 10.1016/j.ygyno.2010.12.140.
• Antiproliferative activity of a phenolic extract from a native Chilean Amaranthaceae plant in drug-resistant ovarian cancer cell linesBrouwer-Visser J, Cossio M, Urzùa N, Montenegro G, Horwitz S, Moreno R, Huang G. Antiproliferative activity of a phenolic extract from a native Chilean Amaranthaceae plant in drug-resistant ovarian cancer cell lines. Gynecologic Oncology 2011, 120: s43. DOI: 10.1016/j.ygyno.2010.12.106.
• Co-expression of GPR30 and ERβ and their association with disease progression in uterine carcinosarcomaHuang GS, Gunter MJ, Arend RC, Li M, Arias-Pulido H, Prossnitz ER, Goldberg GL, Smith HO. Co-expression of GPR30 and ERβ and their association with disease progression in uterine carcinosarcoma. American Journal Of Obstetrics And Gynecology 2010, 203: 242.e1-242.e5. PMID: 20605134, PMCID: PMC2933955, DOI: 10.1016/j.ajog.2010.04.046.
• Insulin-like Growth Factor 2 Expression Modulates Taxol Resistance and Is a Candidate Biomarker for Reduced Disease-Free Survival in Ovarian CancerHuang GS, Brouwer-Visser J, Ramirez MJ, Kim CH, Hebert TM, Lin J, Arias-Pulido H, Qualls CR, Prossnitz ER, Goldberg GL, Smith HO, Horwitz SB. Insulin-like Growth Factor 2 Expression Modulates Taxol Resistance and Is a Candidate Biomarker for Reduced Disease-Free Survival in Ovarian Cancer. Clinical Cancer Research 2010, 16: 2999-3010. PMID: 20404007, PMCID: PMC2887721, DOI: 10.1158/1078-0432.ccr-09-3233.
• Abstract 1809: Reversal of Taxol resistance in ovarian cancer cell lines by IGF pathway inhibitionBrouwer-Visser J, Horwitz S, Huang G. Abstract 1809: Reversal of Taxol resistance in ovarian cancer cell lines by IGF pathway inhibition. Cancer Research 2010, 70: 1809-1809. DOI: 10.1158/1538-7445.am10-1809.
• Abstract A33: in ovarian cancer cell lines resistant to microtubule-stabilizing agents, expression of IGF2 and ABCB1 is increased and IGF1R inhibition restores drug sensitivityBrouwer-Visser J, Horwitz S, Huang G. Abstract A33: in ovarian cancer cell lines resistant to microtubule-stabilizing agents, expression of IGF2 and ABCB1 is increased and IGF1R inhibition restores drug sensitivity. Clinical Cancer Research 2010, 16: a33-a33. DOI: 10.1158/1078-0432.tcme10-a33.
• Extragenital adenosarcoma: A case report, review of the literature, and management discussionHuang GS, Arend RC, Sakaris A, Hebert TM, Goldberg GL. Extragenital adenosarcoma: A case report, review of the literature, and management discussion. Gynecologic Oncology 2009, 115: 472-475. PMID: 19712965, PMCID: PMC4451226, DOI: 10.1016/j.ygyno.2009.07.033.
• A phase II study of weekly topotecan and docetaxel in heavily treated patients with recurrent uterine and ovarian cancersGupta D, Owers RL, Kim M, Kuo DY, Huang GS, Shahabi S, Goldberg GL, Einstein MH. A phase II study of weekly topotecan and docetaxel in heavily treated patients with recurrent uterine and ovarian cancers. Gynecologic Oncology 2009, 113: 327-330. PMID: 19307014, PMCID: PMC4451225, DOI: 10.1016/j.ygyno.2009.02.018.
• Tissue microarray analysis of hormonal signaling pathways in uterine carcinosarcomaHuang GS, Arend RC, Li M, Gunter MJ, Chiu LG, Horwitz SB, Goldberg GL. Tissue microarray analysis of hormonal signaling pathways in uterine carcinosarcoma. American Journal Of Obstetrics And Gynecology 2009, 200: 457.e1-457.e5. PMID: 19200930, PMCID: PMC2676778, DOI: 10.1016/j.ajog.2008.12.012.
• Serum CA125 predicts extrauterine disease and survival in uterine carcinosarcomaHuang GS, Chiu LG, Gebb JS, Gunter MJ, Sukumvanich P, Goldberg GL, Einstein MH. Serum CA125 predicts extrauterine disease and survival in uterine carcinosarcoma. Gynecologic Oncology 2007, 107: 513-517. PMID: 17935762, PMCID: PMC2696225, DOI: 10.1016/j.ygyno.2007.08.060.
• Accuracy of preoperative endometrial sampling for the detection of high-grade endometrial tumorsHuang GS, Gebb JS, Einstein MH, Shahabi S, Novetsky AP, Goldberg GL. Accuracy of preoperative endometrial sampling for the detection of high-grade endometrial tumors. American Journal Of Obstetrics And Gynecology 2007, 196: 243.e1-243.e5. PMID: 17346538, DOI: 10.1016/j.ajog.2006.09.035.
• Survival and toxicity differences between 5‐day and weekly cisplatin in patients with locally advanced cervical cancerEinstein MH, Novetsky AP, Garg M, Hailpern SM, Huang GS, Glueck A, Fields AL, Kalnicki S, Goldberg GL. Survival and toxicity differences between 5‐day and weekly cisplatin in patients with locally advanced cervical cancer. Cancer 2006, 109: 48-53. PMID: 17123270, DOI: 10.1002/cncr.22369.
• Potentiation of Taxol Efficacy by Discodermolide in Ovarian Carcinoma Xenograft-Bearing MiceHuang GS, Lopez-Barcons L, Freeze BS, Smith AB, Goldberg GL, Horwitz SB, McDaid HM. Potentiation of Taxol Efficacy by Discodermolide in Ovarian Carcinoma Xenograft-Bearing Mice. Clinical Cancer Research 2006, 12: 298-304. PMID: 16397055, PMCID: PMC4039036, DOI: 10.1158/1078-0432.ccr-05-0229.
• Consolidation therapy for ovarian cancerHuang G, Goldberg G, Fields A. Consolidation therapy for ovarian cancer. The Women's Oncology Review 2005, 5: 3-8. DOI: 10.3109/14733400500070708.
• Consolidation therapy for ovarian cancerHuang G, Goldberg G, Fields A. Consolidation therapy for ovarian cancer. The Women's Oncology Review 2005, 5: 3-8. DOI: 10.1080/14733400500070708.
• Total laparoscopic hysterectomy versus total abdominal hysterectomy: cohort review of patients with uterine neoplasia.O'Hanlan KA, Huang GS, Garnier AC, Dibble SL, Reuland ML, Lopez L, Pinto RL. Total laparoscopic hysterectomy versus total abdominal hysterectomy: cohort review of patients with uterine neoplasia. JSLS Journal Of The Society Of Laparoscopic & Robotic Surgeons 2005, 9: 277-86. PMID: 16121872, PMCID: PMC3015616.
• Total laparoscopic hysterectomy for oncological indications with outcomes stratified by ageO'Hanlan KA, Huang GS, Lopez L, Garnier AC. Total laparoscopic hysterectomy for oncological indications with outcomes stratified by age. Gynecologic Oncology 2004, 95: 196-203. PMID: 15385132, DOI: 10.1016/j.ygyno.2004.07.023.
• Selective incorporation of total laparoscopic hysterectomy for adnexal pathology and body mass indexO'Hanlan KA, Huang GS, Lopez L, Garnier AC. Selective incorporation of total laparoscopic hysterectomy for adnexal pathology and body mass index. Gynecologic Oncology 2004, 93: 137-143. PMID: 15047227, DOI: 10.1016/j.ygyno.2003.12.020.
• Total laparoscopic hysterectomy: body mass index and outcomes.O'Hanlan KA, Lopez L, Dibble SL, Garnier AC, Huang GS, Leuchtenberger M. Total laparoscopic hysterectomy: body mass index and outcomes. Obstetrics And Gynecology 2003, 102: 1384-92. PMID: 14662231, DOI: 10.1016/j.obstetgynecol.2003.08.018.
• Total Laparoscopic HysterectomyO'Hanlan K, Lopez L, Dibble S, Garnier A, Huang G, Leuchtenberger M. Total Laparoscopic Hysterectomy. Obstetrics And Gynecology 2003, 102: 1384-1392. DOI: 10.1097/00006250-200312000-00028.
• Liposomal Doxorubicin for Treatment of Metastatic Chemorefractory Vulvar AdenocarcinomaHuang GS, Juretzka M, Ciaravino G, Kohler S, Teng NN. Liposomal Doxorubicin for Treatment of Metastatic Chemorefractory Vulvar Adenocarcinoma. Gynecologic Oncology 2002, 87: 313-318. PMID: 12468332, DOI: 10.1006/gyno.2002.6830.